R-GCVP regimen: Difference between revisions
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} Rituximab-Gemcitabine-Cyclophosphamide-Vincristine-Prednisone regimen ==Overview== {{PAGENAME}} refers to a regimen consisting...") |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[rituximab]], [[gemcitabine]], [[cyclophosphamide]], [[vincristine|vincristine (Oncovin)]], and [[prednisone]] used to treat both indolent and aggressive forms of [[diffuse large B-cell lymphoma]].<ref name=" | {{PAGENAME}} refers to a regimen consisting of [[rituximab]], [[gemcitabine]], [[cyclophosphamide]], [[vincristine|vincristine (Oncovin)]], and [[prednisone]] used to treat both indolent and aggressive forms of [[diffuse large B-cell lymphoma]].<ref name="pmid24220559">{{cite journal| author=Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P et al.| title=De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. | journal=J Clin Oncol | year= 2014 | volume= 32 | issue= 4 | pages= 282-7 | pmid=24220559 | doi=10.1200/JCO.2013.49.7586 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24220559 }} </ref> | ||
==Regimen== | ==Regimen== | ||
| Line 20: | Line 20: | ||
==Indications== | ==Indications== | ||
* [[Diffuse large B-cell lymphoma]].<ref name=" | * [[Diffuse large B-cell lymphoma]].<ref name="pmid24220559">{{cite journal| author=Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P et al.| title=De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. | journal=J Clin Oncol | year= 2014 | volume= 32 | issue= 4 | pages= 282-7 | pmid=24220559 | doi=10.1200/JCO.2013.49.7586 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24220559 }} </ref> | ||
==References== | ==References== | ||
Latest revision as of 18:29, 31 March 2015
|
WikiDoc Resources for R-GCVP regimen |
|
Articles |
|---|
|
Most recent articles on R-GCVP regimen Most cited articles on R-GCVP regimen |
|
Media |
|
Powerpoint slides on R-GCVP regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on R-GCVP regimen at Clinical Trials.gov Trial results on R-GCVP regimen Clinical Trials on R-GCVP regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on R-GCVP regimen NICE Guidance on R-GCVP regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on R-GCVP regimen Discussion groups on R-GCVP regimen Patient Handouts on R-GCVP regimen Directions to Hospitals Treating R-GCVP regimen Risk calculators and risk factors for R-GCVP regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for R-GCVP regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Gemcitabine-Cyclophosphamide-Vincristine-Prednisone regimen
Overview
R-GCVP regimen refers to a regimen consisting of rituximab, gemcitabine, cyclophosphamide, vincristine (Oncovin), and prednisone used to treat both indolent and aggressive forms of diffuse large B-cell lymphoma.[1]
Regimen
RRituximab
GGemcitabine
CCyclophosphamide
VVincristine (Oncovin)
PPrednisone
Indications
References
- ↑ 1.0 1.1 Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P; et al. (2014). "De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial". J Clin Oncol. 32 (4): 282–7. doi:10.1200/JCO.2013.49.7586. PMID 24220559.